<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978457</url>
  </required_header>
  <id_info>
    <org_study_id>1104008404</org_study_id>
    <nct_id>NCT01978457</nct_id>
  </id_info>
  <brief_title>Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction</brief_title>
  <official_title>Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      We will develop a procedure for conditioning cue-cocaine associations in human drug users.
      Next, we will reactivate that learning and intervene pharmacologically to prevent the
      reconsolidation of cue-drug memories. We hypothesize that a combined behavioral and
      pharmacological approach will have significant potential for persistently inhibiting relapse.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of patient controlled analgesic (PCA) pump activations (responses)</measure>
    <time_frame>3 days</time_frame>
    <description>Data on cocaine self-administration (total number of responses) will be checked for normality prior to analysis using Kolmogorov-Smirnov statistics and normal probability plots. Data that is not normally distributed will be log transformed. If it remains highly skewed after transformation, it will be analyzed using non-parametric approaches (e.g., a non-parametric, ANOVA-Type Statistic). Normally distributed data will be analyzed employing a mixed model design, 3-way ANOVA with co-factors of placebo vs propranolol (between subjects), non-cocaine predicting cues vs. cocaine predicting cues (within subjects) and non-reactivated cocaine cues vs. reactivated cocaine cues (within subjects).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cocaine Dependent Subjects</condition>
  <arm_group>
    <arm_group_label>cocaine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cocaine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>propranolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cocaine hydrochloride</intervention_name>
    <arm_group_label>cocaine hydrochloride</arm_group_label>
    <arm_group_label>propranolol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <arm_group_label>cocaine hydrochloride</arm_group_label>
    <arm_group_label>propranolol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>cocaine hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 50 years

          2. voluntary, written, informed consent

          3. physically healthy by medical history, physical, neurological, ECG, and laboratory
             examinations

          4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)

          5. recent street cocaine use in excess of that administered in the current study

          6. intravenous and/or smoked (crack/freebase) use

          7. positive urine toxicology screen for cocaine

          8. for females, non-lactating, no longer of child-bearing potential (or agree to practice
             effective contraception during the study), and a negative serum pregnancy (-HCG) test

          9. able to read English and complete study evaluations.

        Exclusion Criteria:

          1. Other drug dependence (except nicotine)

          2. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.),
             unrelated to cocaine

          3. a history of significant medical (cardiovascular) or neurological illness (e.g., prior
             myocardial infarction, current active symptoms of cardiovascular disease / angina,
             evidence of cocaine-related cardiovascular symptoms, prior arrythmias of clinical
             significance, and/or need for cardiovascular resuscitation, neurovascular events such
             as transient ischemic attacks, stroke, and/or seizures)

          4. current use of psychotropic and/or potentially psychoactive prescription medication

          5. seeking treatment for drug abuse/dependence

          6. those having contraindications to beta-blocker administration, including diagnoses of
             asthma, bronchitis, emphysema, or a history of adverse reactions to beta-blockers
             (including propranolol), as well as those with bradycardia and/or first-degree or
             greater heart block by ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Robert Malison</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

